IL13RA2 and glioblastoma: Bielamowicz et al. has also demonstrated that trivalent CAR-T cells targeting HER2, IL13Rα2, and EphA2 demonstrated superior antitumor activity in GBM patient derived xenografts compared to patient-specific single valent and bivalent models (54).